Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.15
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Data is available to registered users only
Buy
Sell